Predictions: ADC, Single-Use Technologies, Regulatory Transparency - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Predictions: ADC, Single-Use Technologies, Regulatory Transparency



CPhI Worldwide and CPhI Pharma Evolution have released the first part of its annual report, which examines the global implications of regulatory failure, single-use technologies, and the potential of antibody drug conjugates (ADC).

The report features article submissions from Piramal Enterprises, Fujifilm Diosynth Biotechnologies. and Vision Consulting.
 
The outlook for the next few years is optimistic for the ADCs market, according to  Piramal Enterprises Executive Director and COO Vijay Shah. He predicts increased global investments, the arrival of a new blockbuster drug to treat solid tumors and expects this class of therapeutics to extend to other indications such as inflammation.

Fujifilm Diosynth Biotechnologies Senior Vice President of R&D and Innovation, Mark Carver warned, however, that unless we move towards a ‘health-based risk assessment’ approach to single-use technologies innovation could be compromised- particularly for promising targets like ADCs that are often required to be manufactured in such facilities. The problem for biologics is that single-use facilities are increasing the costs of development and putting at risk promising targets that are deemed unviable before their true potential has been explored.

Vision Consulting CEO, Dilip Shah, after examining the current regulatory environment, concludes that safety and compliance can be both increased by regulators simplifying and unifying their codes and working closer with industry. However, he anticipates an increased number of deliberate infringements (FDA warning letters), particularly as analytical technologies increase. The implication of these well publicized large pharma infringements is increasingly restrictive regulations will prevent smaller, more innovative players entering the market. The answer, Shah believes, will lie in producing a more transparent process.
 
CPhI and Pharma Evolution will release its remaining annual report findings (10 additional expert submissions) at CPhI 2013, Frankfurt Messe, October 22-24.
 
Source: CPhI Worldwide

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here